Seragon Pharmaceuticals

Sanofi is ploughing ahead with a broad Phase III development program for its oral SERD (selective estrogen receptor degrader) candidate amcenestrant ahead of a key first Phase III readout this year,

Earlier this week (14 September), Roche Holding AG gave a very detailed presentation to analysts to highlight the depth of its R&D pipeline, stocked with 23 late-stage assets, and the Swiss major's

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph

Johnson & Johnson ’s chief scientific officer, Dr. Paul Stoffels, says that the deal structure for the acquisition of Actelion Pharmaceuticals Ltd. , which provides for a spin-out “R&D engine”, is